November 1, 2018 / 9:08 PM / in 15 days

FDA panel votes against Alkermes' depression treatment

Nov 1 (Reuters) - An advisory panel to the U.S. Food and Drug Administration on Thursday voted against approving Alkermes Plc’s experimental depression treatment.

The panel voted 21-2 against the add-on treatment that was aiming to treat major depressive disorder in patients with an inadequate response to standard antidepressant therapies.

The decision comes two days after FDA staff reviewers bit.ly/2QegxPF flagged risks of abuse potential of Alkermes' opioid-based treatment and raised questions on its efficacy. (Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Bernard Orr)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below